These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20844878)

  • 1. Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.
    Fransvea E; Mazzocca A; Santamato A; Azzariti A; Antonaci S; Giannelli G
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):79-86. PubMed ID: 20844878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation.
    Mazzocca A; Fransvea E; Lavezzari G; Antonaci S; Giannelli G
    Hepatology; 2009 Oct; 50(4):1140-51. PubMed ID: 19711426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyelectrolyte capsules as carriers for growth factor inhibitor delivery to hepatocellular carcinoma.
    Baldassarre F; Vergaro V; Scarlino F; De Santis F; Lucarelli G; Torre AD; Ciccarella G; Rinaldi R; Giannelli G; Leporatti S
    Macromol Biosci; 2012 May; 12(5):656-65. PubMed ID: 22392760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
    Fransvea E; Mazzocca A; Antonaci S; Giannelli G
    Hepatology; 2009 Mar; 49(3):839-50. PubMed ID: 19115199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galangin suppresses HepG2 cell proliferation by activating the TGF-β receptor/Smad pathway.
    Wang Y; Wu J; Lin B; Li X; Zhang H; Ding H; Chen X; Lan L; Luo H
    Toxicology; 2014 Dec; 326():9-17. PubMed ID: 25268046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
    Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
    J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma.
    Mazzocca A; Fransvea E; Dituri F; Lupo L; Antonaci S; Giannelli G
    Hepatology; 2010 Feb; 51(2):523-34. PubMed ID: 19821534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
    Li HY; Wang Y; Heap CR; King CH; Mundla SR; Voss M; Clawson DK; Yan L; Campbell RM; Anderson BD; Wagner JR; Britt K; Lu KX; McMillen WT; Yingling JM
    J Med Chem; 2006 Mar; 49(6):2138-42. PubMed ID: 16539403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation.
    Ching YP; Leong VY; Lee MF; Xu HT; Jin DY; Ng IO
    Cancer Res; 2007 Apr; 67(8):3601-8. PubMed ID: 17440071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of a dihydropyrrolopyrazole series of transforming growth factor-beta type I receptor kinase domain inhibitors: discovery of an orally bioavailable transforming growth factor-beta receptor type I inhibitor as antitumor agent.
    Li HY; McMillen WT; Heap CR; McCann DJ; Yan L; Campbell RM; Mundla SR; King CH; Dierks EA; Anderson BD; Britt KS; Huss KL; Voss MD; Wang Y; Clawson DK; Yingling JM; Sawyer JS
    J Med Chem; 2008 Apr; 51(7):2302-6. PubMed ID: 18314943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway.
    Okano J; Nagahara T; Matsumoto K; Murawaki Y
    Basic Clin Pharmacol Toxicol; 2008 Jun; 102(6):543-51. PubMed ID: 18346049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
    Soncini C; Carpinelli P; Gianellini L; Fancelli D; Vianello P; Rusconi L; Storici P; Zugnoni P; Pesenti E; Croci V; Ceruti R; Giorgini ML; Cappella P; Ballinari D; Sola F; Varasi M; Bravo R; Moll J
    Clin Cancer Res; 2006 Jul; 12(13):4080-9. PubMed ID: 16818708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
    Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
    J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.
    Tran TT; Uhl M; Ma JY; Janssen L; Sriram V; Aulwurm S; Kerr I; Lam A; Webb HK; Kapoun AM; Kizer DE; McEnroe G; Hart B; Axon J; Murphy A; Chakravarty S; Dugar S; Protter AA; Higgins LS; Wick W; Weller M; Wong DH
    Neuro Oncol; 2007 Jul; 9(3):259-70. PubMed ID: 17522330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
    Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
    Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
    Cui W; Yu CH; Hu KQ
    Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1.
    Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M
    Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 1-substituted-3(5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl)pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors.
    Jin CH; Krishnaiah M; Sreenu D; Rao KS; Subrahmanyam VB; Park CY; Son JY; Sheen YY; Kim DK
    Bioorg Med Chem; 2011 Apr; 19(8):2633-40. PubMed ID: 21435890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.